NL-OMON55194招募中不适用
on-Ionizing Metabolic Imaging using robust phosphorus MRI to predict treatment efficacy. - NIMI study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 45 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria for pancreatic cancer:
- •To be eligible to participate in this study, a subject must meet all of the
- •following criteria:
- •Patients with (borderline) resectable- or locally advanced pancreatic cancer,
- •with histological or cytological proof, scheduled for standard of care
- •chemotherapy containing fluorouracil, oxaliplatin, irinotecan and leucovorin
- •(FOLFIRINOX) as assessed by a medical oncologist.
- •Tumour size >= 1cm.
- •WHO-performance score 0-1, weight >=40kg
- •Written informed consent.
- •Inclusion criteria healthy volunteers (control group pancreas cohort):
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •Healthy volunteers; No history of cancer, no history of chronic diseases, no
- •history of a pancreatic disease, no elective surgery <8 weeks
- •Age: >= 18yrs
- •WHO-performance score 0-2.
- •Written informed consent.
- •Inclusion criteria for lung cancer:
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •Patients with non-small cell lung cancer, with histological or cytological
- •proof, scheduled for immune checkpoint inhibitors
- •Tumour size >= 2cm.
- •WHO-performance score 0-2, weight >=40kg
- •Written informed consent.
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •Any psychological, familial, sociological, or geographical condition
- •potentially hampering adequate informed consent or compliance with the study
- •Contra-indications for 7T MR scanning, including patients with a pacemaker,
- •cochlear implant or neurostimulator; patients with non-MR compatible metallic
- •implants in their eye, spine, thorax or abdomen; or a non-MR compatible
- •aneurysm clip in their brain; patients with claustrophobia and/or obesitas.
研究者
相似试验
招募中
不适用
Metabolic Imaging to Improve Patient-Specific Therapy Outcomemetastatic colon cancerNL-OMON55904Academisch Medisch Centrum70
已完成
不适用
How well the CTscan findings and findings on PET-CT can predict how a patient with NPC will behaveCTRI/2018/02/011982A100
招募中
1 期
PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma CancerCTIS2024-515850-26-00Institut De Cancerologie De L Ouest52
进行中（未招募）
1 期
PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancerpatients with newly discovered brain metastases (non-small cell lung cancer, breast cancer or melanoma) measuring more than 5 mm and explored on MRIMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001017-37-FRINSTITUT DE CANCEROLOGIE DE L'OUEST52
招募中
不适用
Development of deuterium metabolic imaging to map body biochemistry with MRINL-OMON56442niversitair Medisch Centrum Utrecht40